Public Company Healthcare

Biogen

Cambridge, Massachusetts, United States

Biogen is a biotechnology company that pioneers innovative science to deliver new medicines and create value for patients and shareholders. It focuses on developing and commercializing therapies across neurological and immunology/rare disease areas.

Focus Areas
Biotechnology, Neurology, Immunology
Website
biogen.com

Tracked deals

3

3 tracked deals across 2024-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Biogen Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Biogen. 1 2024 ~3 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
    June 18, 2026
    Buyer
    Biogen Inc.
    Target
    RayThera Inc.
    Seller
    RayThera shareholders
    Industry
    Healthcare Services
    Location
    California, United States
    Type
    Buyout

    Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused biotechnology company, for total consideration of up to $1 billion driven by an upfront payment plus clinical and regulatory milestone payments. The deal is expected to close in the third quarter of 2026, with Biogen taking over development, manufacturing, and global commercialization of RayThera’s small-molecule anti-inflammatory assets.

  • Biogen Acquires Apellis Pharmaceuticals
    March 31, 2026
    Buyer
    Biogen Inc.
    Target
    Apellis Pharmaceuticals, Inc.
    Industry
    Healthcare Services
    Location
    Massachusetts, United States
    Type
    Buyout

    Biogen entered into a definitive agreement to acquire Apellis Pharmaceuticals in a ~$5.6 billion cash deal ($41 per share) that also includes contingent value rights (CVRs) tied to SYFOVRE sales performance. The transaction closed in May 2026 and made Apellis a wholly owned subsidiary of Biogen, adding commercial products EMPAVELI and SYFOVRE to Biogen’s immunology/rare disease portfolio and strengthening its expansion into nephrology.

  • Biogen Acquires Human Immunology Biosciences for up to $1.8B
    May 22, 2024
    Buyer
    Biogen Inc.
    Target
    Human Immunology Biosciences
    Seller
    Human Immunology Biosciences stockholders, ARCH Venture Partners, Monograph Capital, Alpha Wave Global, Arkin Bio Capital, Jeito Capital, Viking Global Investors
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 2 tracked deals by Biogen. Biotechnology Buyers & Acquisitions 1 tracked deal by Biogen. Acquisitions in California 2 tracked deals by Biogen. Acquisitions in Massachusetts 1 tracked deal by Biogen.

Related articles

Selling a company? Get in front of buyers like Biogen

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →